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AbstrAct
Objectives To compare the completeness and agreement 
of prostate cancer data recorded by the National Cancer 
Registration and Analysis Service (NCRAS) with research-
level data specifically abstracted from medical records 
from the Cluster randomised triAl of prostate specific 
antigen (PSA) testing for Prostate cancer (CAP) trial.
Design Cross-sectional comparison study.
Participants We included 1356 men from the CAP trial 
cohort who were linked to the NCRAS registry.
Primary and secondary outcome 
measures Completeness of prostate cancer data 
in NCRAS and CAP and agreement for tumour, node, 
metastases (TNM) stage (T1/T2; T3; T4/N1/M1) and 
Gleason grade (4–6; 7; 8–10), measured by differences in 
proportions and Cohen’s kappa statistic. Data were also 
stratified by year and pre-2010 versus post-2010, when 
NCRAS reporting standards changed.
results Compared with CAP, completeness was lower 
in NCRAS for Gleason grade (41.2% vs 76.7%, difference 
35.5, 95% CI 32.1 to 39.0) and TNM stage (29.9% vs 
67.6%, difference 37.6, 95% CI 34.1 to 41.1). NCRAS 
completeness for Gleason grade (pre-2010 vs post-2010 
31.69% vs 64%; difference 32.31, 95% CI 26.76 to 37.87) 
and TNM stage (19.31% vs 55.50%; difference 36.19, 
95% CI 30.72 to 41.67) improved over time. Agreement for 
Gleason grade was high (Cohen’s kappa, κ=0.90, 95% CI 
0.88 to 0.93), but lower for TNM stage (κ=0.41, 95% CI 
0.37 to 0.51) overall. There was a trend towards improved 
agreement on Gleason grade, but not TNM stage, when 
comparing pre-2010 and post-2010 data.
conclusion NCRAS case identification was very high; 
however, data on prostate cancer grade was less 
complete than CAP, and agreement for TNM stage was 
modest. Although the completeness of NCRAS data has 
improved since 2010, the higher completeness rate in CAP 
demonstrates that gains could potentially be achieved in 
routine registry data. This study’s findings highlight a need 
for improved recording of stage and grade data in the 
source medical records.
IntrODuctIOn
Accurate and complete cancer registry data 
can inform health policy, prioritise the allo-
cation of limited funds available for cancer 
prevention and treatment, and be used 
for research purposes. Bray and Parkin1 2 
outline methods for evaluating the quality of 
cancer registry data, including comparisons 
with other local cancer registries, routinely 
collected data, large-scale research cohorts or 
estimates using incidence rates.
Prostate cancer is the most common cancer 
in males in England, with 39 741 new cases 
registered in 2014.3 The National Cancer 
Registration and Analysis Service (NCRAS) 
collects data on new cases of cancer in 
England,4 including prostate cancer. The 
NCRAS was established in February 2016 to 
incorporate the National Cancer Registry 
Service and the National Cancer Intelligence 
Network, and is now part of Public Health 
England. The ‘Cancer reform strategy’5 
and the ‘Improving outcomes: a strategy 
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Research
strengths and limitations of this study
 ► Cross-sectional study design.
 ► Comparison of English prostate cancer registry with 
independently collected, research-level data from 
a randomised controlled trial on prostate cancer 
screening.
 ► Low level of completeness of tumour, node, 
metastases staging data in National Cancer 
Registration and Analysis Service (NCRAS) overall.
 ► Reporting standards for NCRAS registry changed in 
2010, affecting the consistency of data collection 
and quality across the study period.
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Figure 1 Participant recruitment flow diagram. HSCIC, Health and Social Care Information Centre; NCRAS, National Cancer 
Registration and Analysis Service; PCA, Prostate Cancer.
for cancer’6 reports from the Department of Health in 
England highlighted the need for better information and 
higher quality data to support efforts to improve cancer 
outcomes. The National Cancer Dataset was subsequently 
replaced by the Cancer Outcomes and Services Dataset 
to improve cancer registry data-collection standards in 
England.7 There is some grey literature on the quality 
of the NCRAS cancer registry data, showing low levels of 
completeness of tumour, node, metastases (TNM) stage.8 
However, to our knowledge, comparison studies against 
independently collected data have not yet been published 
for prostate cancer.
The Cluster randomised triAl of PSA testing for Pros-
tate cancer (CAP) trial is a population-based cluster 
randomised controlled trial in England and Wales 
assessing the impact of a single invitation for PSA testing 
for prostate cancer on prostate cancer mortality.9 Within 
this trial, trained researchers extract detailed data from 
the medical records of men who have died with or of 
prostate cancer onto a structured pro forma. These data 
offered the opportunity to compare the completeness 
and agreement of the NCRAS cancer registry data with 
an independent research-level data source.
MAterIAls AnD MethODs
Participant selection
NCRAS collate patient-identifiable demographic and 
cancer-specific clinical information based on the Clinical 
Outcomes and Services Dataset from National Health 
Service (NHS) service providers, unless the patient opts 
out.
The CAP trial involves 416 387 men aged 50–69 years 
from 271 primary care general practitioner practises in 
England and Wales that were randomised between 2001 
and 2007.9 In this trial, these men were flagged with the 
Health and Social Care Information Centre (HSCIC) to 
trace cancer and death registrations. The comparison 
with the NCRAS data restricts the analysis to those from 
CAP practices in England who were deceased. In England, 
362 433 CAP men were successfully traced by the HSCIC 
and 47 556 were notified as having died of any cause. Of 
the men successfully traced and who had died, 2111 were 
identified from HSCIC data as having a prostate cancer 
diagnosis or having prostate cancer listed anywhere on 
the death certificate. These men underwent medical 
record review by specially trained CAP research staff to 
ascertain cause of death independent from information 
held on the death certificate and the cancer registry.9 At 
the time of this analysis, 1356 medical record reviews had 
been completed for men diagnosed with prostate cancer 
between February 2002 and December 2015, who had 
died between April 2003 and October 2015. These men 
were matched to their NCRAS dataset entry using their 
NHS number (see figure 1), then given a unique identi-
fier and merged.
Data
The date of birth provided by the general practitioner 
practicses at the time of recruitment was used to calculate 
age at entry into the CAP study and age at diagnosis.
The NCRAS team extracted available diagnostic data, 
including date of diagnosis, American Joint Committee 
on Cancer10 and Union Internationale Contre le Cancer 
(UICC) TNM staging,11 and Gleason grade12 for the 
current analysis. Clinical TNM stage was derived from 
available imaging data, and pathological TNM stage 
was derived from pathology reports of tissue samples if 
surgery was within 6 months of diagnosis, with final TNM 
staging altered if necessary. NCRAS Clinical TNM stage 
data were combined with pathological stage data by the 
NCRAS team where it was incomplete to produce a ‘best’ 
stage, and these data were used in the analysis.
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The data collected for CAP from the medical records 
included date of prostate cancer diagnosis, diagnostic 
Gleason grade and diagnostic clinical UICC TNM stage. 
These data were extracted for the current analysis, in 
addition to digital rectal examination findings, radiology 
reports and PSA blood results at the time of diagnosis. The 
results of these investigations were used in the current 
analysis to derive clinical TNM stage if this was missing 
from the data extraction. Diagnostic clinical stage, grade 
and other investigations were selected by taking the 
closest record to the date of diagnosis within ±6 months.
TNM stage data gathered for CAP did not always yield a 
complete TxNxMx stage from the clinical record. A prag-
matic, cascading hierarchical approach was therefore 
used if this situation occurred. Any evidence of advanced 
disease (T4 or N1 or M1) was gathered initially, followed 
by evidence of locally advanced disease (T3) and then 
localised disease (T1 or T2). This was done separately for 
NCRAS and CAP stage data.
This study follows the Strengthening the reporting 
of observational studies in epidemiology (STROBE) 
reporting guidelines for observational studies (STROBE 
checklist submitted as online supplementary file 1).
statistical analysis
All analyses were performed using STATA V.14 (StataCorp, 
2015). We compared the completeness of Gleason grade 
and TNM stage between NCRAS and CAP data using 
differences in proportions (with 95% CIs). The agree-
ment between the NCRAS data and CAP data was assessed 
using Cohen’s kappa statistic, with 95% CIs, for Gleason 
grading and TNM staging. We also undertook an anal-
ysis comparing localised (T1/2) versus locally advanced 
(T3) versus advanced (T4 or N1 or M1) prostate cancer. 
Reporting standards for new cases to the registry changed 
in 2010–2011,7 so the completeness of data was also strat-
ified by year of prostate cancer diagnosis and 2002–2009 
vs 2010–2015.
results
The average age at the time of diagnosis of both the 
NCRAS and CAP participants was 75.2 years (SD 5.1).
97.9% (n=1327) of men with prostate cancer notified 
to the NCRAS registry had a complete diagnosis date. 
Gleason grade was entered for 41.2% (95% CI 38.6% to 
43.8%) of NCRAS men. UICC TNM stage was entered for 
29.9% (95% CI 27.5% to 32.5%) (table 1).
Of the CAP trial men with complete medical record 
reviews, 98.5% (n=1336) had complete date of birth and 
diagnosis date. The overall completeness of Gleason 
grade data and TNM stage was 76.7% (95% CI 74.4% to 
78.9%) and 67.6% (95% CI 65.0% to 70.0%), respectively.
The date of diagnosis in the NCRAS registry exactly 
matched CAP trial men in 44.5% (n=583) of cases. The 
median difference in diagnosis date for NCRAS patients 
was 0 day (IQR 0–7) later than CAP men. NCRAS had 
significantly lower overall completeness than CAP for 
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Table 2 Agreement between NCRAS registry and CAP on 
combined Gleason grade
n=1356 NCRAS (n) CAP (n) Kappa (κ) 95% CI
Combined Gleason grade (2002–2009)
4–6 80 202 0.84 0.77 to 0.92
7 97 241 0.86 0.79 to 0.92
8–10 125 337 0.92 0.88 to 0.97
Overall 302 780 0.87 0.84 to 0.92
Combined Gleason grade (2010–2015)
4–6 37 28 0.95 0.89 to 1.00
7 90 93 0.95 0.90 to 0.99
8–10 129 139 0.97 0.93 to 0.99
Overall 256 260 0.93 0.92 to 0.94
Combined Gleason grade (overall)
4–6 117 230 0.88 0.83 to 0.94
7 187 334 0.90 0.86 to 0.94
8–10 254 476 0.94 0.92 to 0.97
Overall 558 1040 0.90 0.88 to 0.93
CAP, Cluster randomised triAl of PSA testing for Prostate cancer; 
NCRAS, National Cancer Registration and Analysis Service.
Table 3 Agreement between NCRAS registry and CAP on 
TNM stage
n=1356 NCRAS (n) CAP (n) Kappa (κ) 95% CI
TNM stage (2002–2009)
T1/T2 91 218 0.55 0.40 to 0.69
T3 21 242 0.33 0.15 to 0.51
T4/N1/M1 72 122 0.53 0.38 to 0.67
Overall 184 582 0.47 0.43 to 0.50
TNM stage (2010–2015)
T1/T2 64 57 0.45 0.28 to 0.62
T3 40 90 0.25 0.08 to 0.41
T4/N1/M1 117 84 0.41 0.28 to 0.55
Overall 221 231 0.34 0.27 to 0.37
TNM stage (overall)
T1/T2 155 275 0.53 0.42 to 0.64
T3 61 332 0.29 0.17 to 0.41
T4/N1/M1 189 206 0.47 0.37 to 0.57
Overall 405 813 0.41 0.37 to 0.51
CAP, Cluster randomised triAl of PSA testing for Prostate cancer; 
NCRAS, National Cancer Registration and Analysis Service; TNM, 
tumour, node, metastases.
Gleason grade (difference in proportions 35.6%, 95% CI 
32.1% to 39.0%), and TNM stage (37.6%, 95% CI 34.1% 
to 41.1%), although the difference in completeness of 
Gleason grade (1.00%, 95% CI −5.63% to 7.63%) and 
TNM stage (11.75%, 95% CI 5.05% to 18.45%) data was 
much smaller from 2010 onwards.
Table 2 shows agreement on Gleason grade data in the 
registry and the CAP trial, which was strong. Agreement 
was high for combined (κ=0.90, 95% CI 0.89 to 0.92) 
Gleason grade overall. There was a trend towards higher 
agreement in 2010–2015 compared with 2002–2009 for 
low, moderate and high combined Gleason grade. This 
level of agreement was maintained across individual levels 
of primary (κ=0.84, 95% CI 0.82 to 0.86) and secondary 
Gleason grades (κ=0.80, 95% CI 0.79 to 0.83).
Table 3 shows agreement on overall UICC TNM 
staging. The levels of agreement for overall stage accuracy 
were weak to moderate. Similar levels of agreement were 
found when considering the data categorised as localised 
(T1/2, κ=0.53, 95% CI 0.42 to 0.64), locally advanced 
(T3, κ=0.29, 95% CI 0.17 to 0.41) and advanced (T4 or 
N1 or M1, κ=0.47, 95% CI 0.37 to 0.57). These findings 
were consistent when comparing data from 2002–2009 
with 2010–2015.
DIscussIOn
There were mixed levels of completeness and agree-
ment of stage and grade information comparing 
NCRAS with CAP research-level data. We showed a 
high level of completeness for case identification and 
diagnosis dates in both cohorts. NCRAS complete-
ness for Gleason grade was moderate and TNM stage 
completeness was low. From 2010, the completeness of 
stage and grade data in the NCRAS registry increased. 
Completeness in CAP remained consistently high 
throughout the study period. Agreement between 
NCRAS and CAP was high for Gleason grade and 
moderate for TNM stage.
The completeness of case capture and diagnosis 
date is consistent with the UK and Ireland Association 
of Cancer Registries’ most recent performance indi-
cators.13 Our results are similar to those from valida-
tion studies of cancer registries in other countries. 
Estimates of completeness for registries in Ireland,14 
Sweden,15 16 Bulgaria17 and Norway18 were gener-
ally high, ranging from 91% to 97%. These studies 
compared registry data with other population registries 
or primary care records. None of them used an inde-
pendently collected research-level cancer trial dataset 
for comparison. Tomic et al16 found a higher level of 
agreement in Sweden for both TNM staging (83%) 
and Gleason grading (97%) when compared with our 
study. This could be due to the lower level of grade and 
stage completeness in our study and changes in the 
UICC TNM classification during the study period, and 
the fact that Tomic et al compared two cancer regis-
tries that gathered prostate cancer data on the same 
population.
The strengths of the data used in the current anal-
ysis to compare completeness and agreement with the 
NCRAS cancer registry were that they were obtained 
through extensive medical notes review by trained 
researchers. Furthermore, almost every CAP trial 
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participant’s diagnosis had been notified to the NCRAS 
registry, allowing a thorough comparative analysis.
The completeness of UICC TNM stage data in the 
registry was moderate, making it more difficult to 
draw conclusions about the accuracy of TNM staging. 
A possible reason for the differences in agreement 
between NCRAS and CAP could be due to the fact that 
NCRAS more commonly partially or completely used 
pathological TNM staging compared with CAP. Distin-
guishing TNM stage of prostate cancer radiologically, 
particularly T1b vs T2, is an evolving area,19 and this may 
explain some of the difficulties in reporting. Reporting 
standards for NCRAS cancer registries changed in 2010 
and completeness improved after the changes were 
made.7
Our findings suggest that prostate cancer data in 
the NCRAS cancer registry are complete in terms of 
identifying and recording new cases. While the agree-
ment for Gleason grade was high, the completeness 
and agreement of TNM stage data were lower for the 
years covered in this analysis, highlighting a need for 
improved recording of these data in the source medical 
records. This study also demonstrates how trial data can 
be verified for completeness and accuracy using empir-
ical data. Completeness of NCRAS data has improved 
since 2010, however the higher completeness rate in 
CAP highlights what further gains could potentially be 
achieved in routine registry data. Complete and accu-
rate national cancer registries are vital to inform health 
policy, healthcare spending and research.
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